Journal article

Positron-emission tomography reveals early flare in uptake of FLT in tumors following chemotherapy with gemcitabine

GA McArthur, RM Hicks, DR Shalinsky, D Binns, C O’Kane, A Hogg, R Fisher, TJ McCarthy, KA Anderes

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2007


2537 Background: Strategies to monitor molecular & cellular responses to novel cell cycle targeting agents are vital to provide proof of their mechanism & biological activity. In developing biomarkers for the novel chk1 inhibitor, PF-477736, we demonstrated that gemcitabine chemotherapy induced a significant increase, or flare, in uptake of the PET tracer, 3’-deoxy-3’flurothymidine (FLT), into tumor xenografts 24 h after dosing (Proc ASCO 24:A3045, 2006). We postulated that an early flare in FLT may also occur following gemcitabine therapy in human tumors. Methods: Eligible patients had at least 1 malignant lesion identified by CT scan outside of a previous radiation field. Patients receive..

View full abstract

University of Melbourne Researchers

Citation metrics